# Determination of Released Payload Species of Antibody Drug Conjugates with Noncleavable Linkers by High Resolution Mass Spectrometry and MetabolitePilot<sup>™</sup> 2.0 Software

Ian Moore and Yuan-Qing Xia

SCIEX, Concord, ON, Canada; SCIEX, 71 Four Valley Drive, Concord, ON, L4K 4V8 Canada

### **ABSTRACT**

In this study the Advanced Biotransform Solution and Antibody Drug Conjugate (ADC) specific workflow features of the new MetabolitePilot<sup>™</sup> 2.0 software were used to identify released payload products and metabolites from two noncleavable linker ADCs after incubation with human liver lysosomes (HLL) and S9 fraction. The commercial ADC trastuzumab emtansine and the ADC mimic from Sigma were used as example compounds.

### **INTRODUCTION**

The number of possible species that can be generated when considering the metabolic/catabolic fate of an Antibody Drug Conjugate (ADC) is vast. One must consider payload-linker species with one or more amino acids attached plus potential biotransformations of the linker and/or payload in addition to any cleavage or degradation products. Not all ADCs are completely stable in circulation and nonspecific release of the drug or transfer of the drug to other serum components has been reported. Understanding and identifying the major released drug-containing species and metabolites is an essential part of ADC drug development. Until recently no specific ADC metabolism workflow existed in a commercial metabolite ID software package making consideration of all these species a difficult process



Figure 1. The structures of the linker plus payload of trastuzumab emtansine (T-E) and SigmaMAb Antibody Drug Conjugate mimic (MSQC8), sites of conjugation to the mAb are highlighted in red.

### **METHODS**

### Sample Preparation:

- 1. 50 µg/mL ADC incubated with 0.25 mg/mL HLL or 1 mg/mL S9, 37°C.
- 2. Total volume = 200  $\mu$ L (70  $\mu$ L H<sub>2</sub>O+20  $\mu$ L catabolism buffer pH 5+100  $\mu$ L analyte stock).
- 3. Remove 50 µL aliquot at 1, 2, 4 and 26 hours.
- 4. Add 250 µL of cold ACN, then centrifuge at 14 x g for 15 minutes.
- 5. Remove supernatant to a clean tube and dry under vacuum at 37 °C.
- 6. Reconstitute in 50 µL 5% mobile phase B for injection.

### LC-MS Data Collection:

- SCIEX TripleTOF® 6600 System using SWATH® acquisition (Advanced Biotransform Solution)
- 25 variable SWATH windows focused around 1103.47 for T-E and 789.37 for MSQC8
- Total scan time for the SWATH method was 850 ms
- SCIEX Exion AD system
- Phenomenex Aeris C18 Peptide column (2.0 x 150 mm), 1.7 µm
- Elution was performed using a linear gradient from 5% to 80% B over 26 mins. A –  $H_2O$ , B – ACN 0.1%  $CH_2O_2$



### Data Processing with MetabolitePilot 2.0:

Peak Finding Algorithms:

- characteristic product ion
- MSQC8 Predicted and generic TOF MS peak finding
- Charge state 1 to 3
- Biotransformations

Payload Cleavages

- Break 2 bonds, filtered by site of attachment Antibody Details
- Non-specific cleavage of 2 bonds, break disulfide bonds
- Max aa count = 5
- T-E trastuzumab, lysine conjugation with loss of water • MSQC8 – SigmaMab, cysteine conjugation with addition

New 🔻	Open Save	Save As	i	Delete		Method	type: ADC		
Compound Informa	ation	Select From Library.		Structure					0
Compound name:	DM1-MCC					ĺ			
Chemical formula:	C47H63CIN4O14S		1			016.0	<b>_</b> 0%		
Polarity:	Positive      Negative		,			04 H 05			
Charge state: From:	1 • To: 3 •	0				CH- CH3	Si.	$\sim$ $\sim$	
on type:	[M+H] <sup>+</sup>	-				$\gamma \gamma \gamma$	/ <mark></mark>	્પ્દુા	~
m/z: 975.3823						y			
						CH3"			
ah Einding Planta		Generic Para	meters	Compound-Specifi	c Parameters				
e this algorithm:	UV	Cleavage M	etabolite	s Isotope Pattern	Product lons	and Neutral Losses	Antibody Details		
OF MS									
Predicted metab	bolites	Poten	tial Con	pound Cleavages					
<ul> <li>Predicted metab</li> <li>Generic peak fin</li> <li>Apply mass de</li> </ul>	bolites nding sfect filter	Poten	tial Con um bon:	for the break: 2	- En	eak ring bonds	Only break C-N bo	nds 📃 Filter	by
<ul> <li>Predicted metab</li> <li>Generic peak fir</li> <li>Apply mass de</li> <li>Apply charge s</li> </ul>	bolites inding sfect filter state filter	Poten Maxim Cleave	tial Con um bon: iges selé	fs to break: 2	Bre	eak ring bonds	Only break C-N bo	nds 📄 Filter	by
Predicted metab     Generic peak fir     Apply mass de     Apply charge s     Mass defect	bolites nding sfect filter state filter	Poten Maxim Cleave	tial Con um bon: Iges sele	ts to break: 2 acted: 73	Bre	eak ring bonds	Only break C-N bo	nds 📄 Filter	by
Predicted metab     Generic peak fir     Apply mass de     Apply charge s     Mass defect     Isotope pattern	bolites nding sfect filter state filter	Poten Maxim Cleavs	tial Con um bono iges sele	to break: 2 acted: 73 Loss from Pa	srent	Neutral Formu	Only break C-N bo	m/z [M+2HJ2+	by [I
Predicted metab Generic peak fir Apply mass de Apply charge s Mass defect I sotope pattern	bolites nding sfect filter state filter	Poten Maxim Cleave	ial Con um bono iges sele ] C21	appoind Cleavaget to break: 2 acted: 73 Loss from Pa BH35CIN2O8 and C	arent	Neutral Formu C18H26N2O6S	Only break C-N bc           ia         m/z [M+H]+           399.1584           413.1741	m/z [M+2H]2+ 200.0629	by [I
Predicted metab Generic peak fin Apply mass de Apply charge s Mass defect I isotope pattern DF MSMS Find characteris	bolites hding fect filter state filter state filter	Poten Maxim Cleave	tial Con um bon: iges sek ] C21 ] C22	acted: 73 Loss from Pa BH35CIN2O8 and C BH35CIN2O8	arent	Neutral Formu C18H26N2O6S C19H28N2O6S C19H28N2O6S	Only break C-N bo m/z [M+H]+ 399.1584 413.1741	m/z [M+2H]2+ 200.0629 207.0907	by [1
Predicted metab Generic peak fir Apply mass de Apply charge s Mass defect Isotope pattern OF MSMS Find characteris All specified ior	colites nding viect filter state filter state filter	Poten Maxim Cleave	tial Con um bond iges self ] C21 ] C22 ] C22 ] C23	appoind Cleavaget is to break: 2 is to break	arent H2	Neutral Formu C18H26N2O6S C19H28N2O6S C18H26N2O7S C18H26N2O7S	Only break C-N bo m/z [M+H]+ 399.1584 413.1741 415.1533	m/z [M+2H]2+ 200.0629 207.0907 208.0603 245.0881	by [T
Predicted metab Generic peak fir Apply mass de Apply charge s Mass defect Isotope pattern FMSMS Find characteris All specified ior	bolites nding freet filter state filter dis product ions ns	Poten Mascim Cleave	tial Con um bond ges sele ] C21 ] C21 ] C21 ] C21	sto break: 2 sto break: 2 Loss from Pa BH35CIN2O8 and C BH35CIN2O8 BH35CIN2O7 and C BH35CIN2O7 BH35CIN2O7	arent H2	Neutral Formu           C18H26N206S           C19H28N206S           C19H28N207S           C19H28N207S           C19H28N207S	Only break C-N bc           Image: m/z [M+H]+           399.1584           413.1741           415.1533           429.1690           515.2752	m/z [M-2H]2+ 200.0629 207.0907 208.0603 215.0681	by [1
Predicted metable redicted metable redi	colites ding frect litter state filter dis product ions ns ions tic neutral preses	Poten Massim Cleave V V V V V V V V V V V V V V V V V V V	tial Con um bon: iges sele ] C2i ] C2i ] C2i ] C2i ] C2i	appound Cleavage:           is to break:         2           iscled:         73           Loss from Pr           BH35CIN208 and C           BH35CIN208           BH35CIN207 and C           BH35CIN207           H and C19H26N20           H and C19H26N20	arent H2	Neutral Formu C18H26N206S C19H28N206S C19H28N20FS C19H28N207S C28H38N207 C28H38N207	Only break C-N bc           ia         m/z [M+H]+           399.1584         413.1741           415.1533         429.1690           515.2752         510.2752	nds Filter m/z [M+2H]2+ 200.0629 207.0907 208.0803 215.0881 258.1412 269.4465	by [1
Predicted metab     Predicted metab     Generic peak fir     Apply mass de     Apply charge s     Mass defect     Isotope pattern     Find characteris     All specified ior     At least     Tind characteris     All specified ior     All	bolites hding fice filter state filter dic product ions ns ions dic neutral iosses see	Poten Maxim Zeauvi Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	tial Con um bons liges sele ] C21 ] C22 ] C22 ] C23 ] C1- ] CH	appound Cleavage:           is to break:         2           iscled:         73           Loss from Pr           BH35CIN208 and C           BH35CIN208           BH35CIN207 and C           BH35CIN207           H and C19H26N2           20 and C19H26N2           H and C19H26N2	Brent H2 C75 C75 C75 C75 C75 C75 C75 C75	Neutral Formu           C18H26N206S           C19H28N206S           C19H28N207S           C19H28N207S           C28H38N207           C27H35CIN206	Only break C-N bo           Is         m/z [M+H]+           399,1584           413,1741           415,1533           429,1690           515,2752           519,2256           519,2256           519,2256	m/s Filter m/z [M+2H]2+ 200.0629 207.0907 208.0803 215.0681 258.1412 260.1165 266.1367	[I
? Predicted metal: ? Generic peak fin Apply mass de Apply charge s ] Mass defect ] Isotope pattern >F MSMS ? Find characteris All specified for ? At least 1 ] Find characteris All specified to All specified to All specified to All specified to All specified to All specified to	colles ding fice: filter state filter site product ions ns site neutral losses soes ions .	Poten Masaim Cleavy III IIII IIIIIIIIIIIIIIIIIIIIIIIIIII	tial Con um bons liges sele ] C21 ] C22 ] C22 ] C23 ] C4 ] C4	appound Cleavaget           is to break:         2           isted:         73           Loss from Pr           BH35CIN208 and C           BH35CIN208           BH35CIN207 and C           BH35CIN207           H and C19H26N2           20 and C19H26N2           H and C19H26N2           H and C19H26N2	arent         H2           H2         Corrs           Corrs         Corrs           Corrs         Corrs	Neutral Formu           C18H26N206S           C19H26N206S           C19H26N20FS           C19H28N20FS           C28H38N20F           C27H35CN20F           C28H38N20F           C28H38N20F	Only break C-N bo           Is         m/z (MH)+           399.1584         413.1741           415.1533         429.1890           515.2752         519.2256           531.2701         531.2701	nds Filter m/z [M+2H]2+ 200.0629 207.0907 208.0803 215.0881 258.1412 260.1165 266.1387 266.1387	[I
Predicted metab Predicted metab Generic peak fir Apply mass de Apply mass de Apply charge s All specified ior All specified ior All specified lor All	obles ding ding dic filter tate filter dic product ions ns bins bins the utrail losses sees bioses bioses	Potent Masaim Cleavy 22 22 22 22 22 22 22 22 22 22 22 22 22	tial Con um bons liges sele liges sele liges (22) C22 C22 C22 C22 C23 C24 C24 C24 C24 C24 C24 C24 C24	appound Cleavaget           is to break:         2           isted:         73           Loss from Pit           SH35CIN206 and C           SH35CIN206           SH35CIN207 and C           SH35CIN207           H and C19H26N207           H and C19H26N202           H and C19H26N202           H and C19H26N207           H and C19H26N207           H and C19H26N207	E Bre     Free     Free	Neutral Formu           C18H26N206S           C18H26N206S           C18H26N20FS           C18H26N20FS           C18H26N20FS           C18H26N20FS           C18H26N20FS           C28H38N20F           C2H35N20FS           C28H38N20F           C28H38N20F           C28H38N20F           C28H370N206           C28H370N208	Only break C-N bc           m/z           (M+H)+           399,1584           413,1741           415,1533           429,1690           515,2752           519,2256           531,2701           533,2413	nds Filter m/z [M+2H]2+ 200.0629 207.0907 208.0803 215.0881 258.1412 260.1165 266.1387 267.1243	
Predicted metal     Generic peak fit     Generic peak fit     Apply mass de     Apply charge s     Mass defect     Isotope pattern      TOF MSMS     Find characteris     All specified lor     A	obles  didig didig didig dided filter diste filter diste filter diste filter diste neutral losses dises losses los	Poten Massim Cleared 22 22 22 22 22 22 22 22 22 22 22 22 22	tial Con um bon ges sek ] C21 ] C21 ] C21 ] C21 ] C1-1 ] C1-1	appound Cleavager           is to break:         2           is to break:         2           Loss from Pr         3           BH35CIN2O8 and C         3           BH35CIN2O8 and C         3           BH35CIN2O8 and C         3           BH35CIN2O7 and C         3           BH35CIN2O7 and C         3           BH35CIN2O7 and C         3           H and C19H26N2         20 and C19H26N2           H and C19H26N27         3           C0 and C19H26N27         3           C0 and C19H26N2         3           D0 and C19H26N2         3           D0 and C19H26N2         3           D0 and C19H26N2         3           D0 and C19H26N2         3	Image: Second	Neutral Formu           C18H28N206S           C19H28N206S           C19H28N20FS           C19H28N20FS           C19H28N20FS           C19H28N20FS           C19H28N20FS           C19H28N20FS           C28H3N20F           C2H350H20FS           C28H37CIN206           C28H37CIN206           C27H35CIN207	Only break C-N bc           m/2 (M+H)+           399.1584           413.1741           415.1533           429.1690           515.2752           519.2256           531.2701           535.2206           535.2206	nds Filter m/z [M+2H]2+ 200.0629 207.0907 208.0803 215.0881 258.1412 260.1165 266.1387 266.1387 267.1243 268.1367 267.243 268.1367 267.243 268.1367 267.243 268.1367 267.243 268.1367 267.243 268.1367 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 267.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.243 277.24	p



Figure 3. The payload cleavage metabolites and antibody catabolite details from the processing method used for

- T-E Predicted and generic TOF MS peak finding plus TOFMSMS of at least 1
- Loss of water, demethylation, hydrogenation and dihydrogenation





### RESULTS

A total of 59 potential metabolites of T-E were found in the 26 hour time point of the incubation with HLL within the retention time window of 3 to 29 minutes. As T-E contains a non-cleavable linker the released payload species consists of DM1-MCC plus a lysine residue. Using the results workspace of MetabolitePilot 2.0 Software this released product was found at retention times 15.01 and 15.27 minutes as the released payload is a pair of diastereomers (Figure 4). The released payload was found in the TOF MS spectra as singly charged and doubly charged protonated species and as the singly charged sodium adduct all within  $\pm 2.0$  ppm (m/z 1103.4763, 552.2145 and 1125.4573).



After identification of the released payload species in the results workspace further confirmation was performed using MS/MS in the interpretation workspace (Figure 4). The assign fragments feature is used to calculate potential structures for the fragments and neutral losses in the MS/MS spectrum. For the singly charged released payload species 4 common product ions (indicated in orange) were found in the MS/MS at 140.0701 467.2086, 485.2209 and 547.2208 within ±4.0 mDa.

Four other catabolites containing the unmodified DM1-MCC conjugated to a dipeptide sequence were found that had at least two product ions in common and appeared as a pairs of diastereomeric peaks. Table 1 lists their identity and sequence. No catabolites conjugated to anything larger than a dipeptide were confirmed in the sample, this likely due to a combination of the length of the incubation and the sample work-up which involved an organic precipitation.

> Table 1. List of released payload plus linker species from the incubation of T-E with HLL and S9. \_\_\_\_\_

Catabolite	RT 1	RT 2	
Parent	17.6		
Parent+YK	15.17	15.40	
Parent+K	15.01	15.27	
Parent+KV	15.1	15.4	
Parent+KS	15.0	15.3	
Parent+KA	14.8	15.1	



Figure 4. The results and interpretation MetabolitePilot 2.0 results of species (payload+linker+lysine) from incubation of T-E with human liver

> \_\_\_\_\_

MSQC8 is a cysteine linked ADC that is not a therapeutic molecule but an ADC mimic. A reference MS/MS spectrum was not available for the dansyl fluorophore plus linker so peak finding was performed using predicted metabolites and generic peak finding. A total of 119 potential metabolites and catabolites were found within the retention time window of 3 to 25 minutes and  $\pm 5.0$  ppm. The released payload species (dansyl+linker+cysteine) was found in both single and doubly charged forms at 14.92 minutes as a single peak.





The Figure 5. results nterpretation workspace displaying results of the released pavload species (payload+linker+cysteine) from the incubation of MSQC8 with human liver lysosomes

The interpretation workspace (Figure 5) was then used to assign peaks in the MS/MS, this was a critical step as no reference spectra of the payload and linker was available. The structural interpretation tool assigned structures to four of the ions in the MS/MS all within  $\pm 2.0$  mDa and three of the four ions contained the dansyl ring, Table 2.

Among the list of potential catabolites/metabolites a putative demethylated metabolite of the payload+linker+cysteine was identified in the TOF MS at 13.05 minutes. Again the interpretation workspace was used to assign ions in the MS/MS to the metabolite structure for confident ID. Three ions in the MS/MS spectra were found with a mass difference of 14 Da when compared with the ions assigned in the released payload species. Based on the assigned fragment structures from MetabolitePilot<sup>™</sup> 2.0 software and their mass accuracies; the site of demethylation was assigned to the dimethylamino group of the naphthalene ring of the payload (Table 2).



**Figure 6.** The interpretation workspace displaying the MS/MS interpretation results for the demethylated metabolite of the MSQC8 payload.

with H	S9.							
Ma (Par		M (						
789.:		77						
449.2	2599		43					
C:\ProgramData\SCIEX\MetabolitePilotData 2.0\Cor								
<u>File Edit Setup T</u>	ools <u>H</u> elp							
Batch Results Correlation Workflow Compound Library Processing Parameters Create Report	Potentia Piot 474 2 475 2 476 2 477 2 477 2 478 2 479 2 480 2 499 2 490 2 490 2 490 2 490 2 490 2 400 200 200 200 200 200 200 200 200 200	Metal Peek ID C411 C419 C423 C423-1 C439 C443-1 C450 C443-1 C450	Delites: 4					

## **CONCLUSIONS**

The SCIEX Advanced Biotrans solution with the TripleTOF® 6600 system and new MetabolitePilot 2.0 software effectively addresses the complex task of performing metabolite and catabolite ID on ADCs from comprehensive peak detection with SWATH® acquisition to metabolite finding. MetabolitePilot 2.0 software features a dedicated ADC processing workflow that performs targeted searching for all components of the ADC: payload, linker and antibody plus cleavage metabolites and biotransformations.

# **ACKNOWLEDGEMENTS**

Thank you to Chris Bohl of Xenotech for helpful discussions and providing human liver lysosomes and S9 fraction.

# **TRADEMARKS/LICENSING**

AB Sciex is doing business as SCIEX. © 2017 AB Sciex. For Research Use Only. Not for use in diagnostic procedures. The trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners. AB SCIEX<sup>™</sup> is being used under license. Document number: RUO-MKT-10-5808-A



Table 2. List of ions with m/z shifts of 14 Da found in the MS and MS/MS spectra of MSQC8 after incubation





Figure 6. The correlation workspace of MetabolitePilot 2.0 software displaying results of the released payload species (payload+linker+lysine) from the incubation of T-E with human liver lysosomes. In this workspace overlaid XICs from the LC chromatogram, MS and MS/MS spectra are overlaid The most abundant species pavload+linker+lysine. payload+linker plus dipeptide

fragments containing lysine were also observed.